FIELD: pharmaceuticals.
SUBSTANCE: method for treating non-small-cell lung cancer (NSCLC) in a patient, including the administration of MEDI4736 and tremelimumab, where (i) the administration can give an average Cmax with a value of 266-300 μg/ml MEDI4736 and Cmax with a value of 25-30 μg/ml tremelimumab; (ii) MEDI4736 is administered 1 hour after tremelimumab administration and (iii) MEDI4736 and tremelimumab are administered every 4 weeks for a maximum of 16 weeks.
EFFECT: safety and synergistic effectiveness of the combination.
9 cl, 37 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO B7-H1 AND TO CTLA-4 FOR TREATING NON-SMALL-CELL LUNG CANCER | 2015 |
|
RU2702332C2 |
| ANTIBODIES TO B7-H1 FOR TREATING TUMOURS | 2014 |
|
RU2817281C2 |
| COMBINATION | 2015 |
|
RU2744841C2 |
| AVELUMAB DOSING MODE FOR TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2777363C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| DOSING REGIMENS WITH INTRODUCTION OF BISPECIFIC ANTIBODIES AGAINST LAG-3/PD-L1 | 2020 |
|
RU2818587C2 |
| APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS | 2019 |
|
RU2783846C1 |
